Design Therapeutics Financials - Benzinga

SPY764.20−0.18%QQQ738.23+0.23%BTC/USD83,266.86−0.23%DIA511.50−0.49%GLD381.96+1.07%TLT78.17−0.58%

Design Therapeutics Inc

DSGNNASDAQ

Trade with Public

Trade with Public

$12.12

-0.24-1.94%

Last update: Sep 29, 9:29 AM

Overview News Earnings Forecast Events Price TargetsFinancialsSentiment Ownership Compare Options Stock Report

Design Therapeutics Financials

Design Therapeutics (DSGN) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Design Therapeutics Q2 EPS $(0.32) Beats $(0.34) Estimate

Design Therapeutics (NASDAQ:DSGN) reported quarterly losses of $(0.32) per share which beat the analyst consensus estimate of $(0.34) by 5.88 percent. This is a 5.88 percent increase over losses of $(0.34) per share

Benzinga Newsdesk

PRO
Design Therapeutics Q1 EPS $(0.29) Beats $(0.34) Estimate

Design Therapeutics (NASDAQ:DSGN) reported quarterly losses of $(0.29) per share which beat the analyst consensus estimate of $(0.34) by 14.71 percent. This is a 6.45 percent increase over losses of $(0.31) per share

Benzinga Newsdesk

PRO
Design Therapeutics Q4 EPS $(0.27) Beats $(0.35) Estimate

Design Therapeutics (NASDAQ:DSGN) reported quarterly losses of $(0.27) per share which beat the analyst consensus estimate of $(0.35) by 23.3 percent. This is a 12.5 percent decrease over losses of $(0.24) per share from

Benzinga Newsdesk

PRO
Design Therapeutics Q3 EPS $(0.30) Beats $(0.34) Estimate

Design Therapeutics (NASDAQ:DSGN) reported quarterly losses of $(0.30) per share which beat the analyst consensus estimate of $(0.34) by 11.76 percent. This is a 30.43 percent decrease over losses of $(0.23) per share

Benzinga Newsdesk

PRO
Design Therapeutics Q2 EPS $(0.34) Misses $(0.33) Estimate

Design Therapeutics (NASDAQ:DSGN) reported quarterly losses of $(0.34) per share which missed the analyst consensus estimate of $(0.33) by 3.03 percent. This is a 61.9 percent decrease over losses of $(0.21) per share

Benzinga Newsdesk

PRO
Design Therapeutics Q1 EPS $(0.31) Misses $(0.28) Estimate

Design Therapeutics (NASDAQ:DSGN) reported quarterly losses of $(0.31) per share which missed the analyst consensus estimate of $(0.28) by 10.71 percent. This is a 55 percent decrease over losses of $(0.20) per share

Benzinga Newsdesk